Echo IQ Ltd. disclosed a regulatory detour for its AI heart failure diagnostic ambitions after the FDA issued a not substantially equivalent determination for the company’s initial 510(k) application for Echosolv HF. The decision delays potential U.S. commercial clearance and keeps the pathway under review for further evidence. The broader regulatory theme was also echoed by a separate U.K. blueprint recommending life-cycle oversight for AI-enabled healthcare products, arguing that a one-time approval model is inadequate as these systems iterate and behave differently across settings. For biotech-adjacent digital health, the net effect is clear: regulators are tightening how they evaluate evidence, performance stability, and real-world behavior—especially when the technology is adaptive or updates post-market.